The Global Medtech Industry: Rewiring Medtech in a Post-Pandemic World
The medtech industry is undergoing rapid change to address evolving global market dynamics. This has been further accelerated by the pandemic. This white paper from IQVIA – an associate member of AdvaMed® – discusses how global markets and specific therapeutic areas are poised for growth over the next decade. Read this white paper to help inform business strategy.
Related Reading
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
Navigating the ACCESS & TEMPO Models: A Direct Dialogue with CMMI & FDA Leaders
On Demand
Watch AdvaMed’s® exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS & TEMPO Model. Attendees will gain critical insights into model performance metrics, payment pathways, and opportunities for the MedTech industry.
News / Global & Trade / Tariffs
ICYMI: AdvaMed’s Scott Whitaker on Supreme Court Tariffs Decision, Next Steps
February 23, 2026
Scott Whitaker, president and CEO ofAdvaMed®, the world’s largest trade association representing medtech innovators, released the following statement after Fridays’ Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
The Supreme Court Struck Down IEEPA Tariffs – What Medtech Needs To Know
March 31, 2026
1:00 PM
Now On Demand
News / Global & Trade / Supply Chain / Tariffs
AdvaMed® Supports United States-Mexico-Canada Agreement Renewal
February 12, 2026
WASHINGTON—AdvaMed, the MedTech Association®, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker,AdvaMed® president and CEO, made the following comment on the renewal.
Resource / AdvaMed Advancements / Global & Trade / Tariffs
AdvaMed® Plays Tariff Chess, Trump Plays Checkers
February 4, 2026
As tariff uncertainty continues in 2025,AdvaMed® plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Global & Trade / Tariffs
AdvaMed® Advancements: Q4 2025 Report
January 27, 2026
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
News / China / Global & Trade / Supply Chain / Tariffs
AdvaMed® Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech
November 3, 2025
WASHINGTON—AdvaMed, the MedTech Association®, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed® Advancements: Q3 2025 Report
October 31, 2025
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment,AdvaMed® remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more